Tesofensine is not a peptide but a substance that raises levels of serotonin, norepinephrine, and dopamine in the brain and thereby reduces appetite. It is being studied for weight loss; it was originally developed for Parkinson's disease.
Not a peptide. Small molecule C₁₇H₂₃Cl₂NO. Triple SNDRI (serotonin + norepinephrine + dopamine reuptake inhibitor). ~332 Da.
Phase II Lancet (n=203): −10.6% over 24 weeks at 1.0 mg, −9.2% at 0.5 mg. At the time of publication (2008), twice as potent as existing drugs. Originally developed for Parkinson's disease.
Simultaneous ↑serotonin (↓appetite), ↑norepinephrine (↑thermogenesis, ↑energy expenditure), ↑dopamine (↓food reward). Suppresses GABA neurons of the lateral hypothalamus. It is not an amphetamine and does not cause euphoria at therapeutic doses.
Studies used 0.5 mg/day orally (the optimum balance of effect and tolerability). Tesomet = tesofensine 0.5 mg + metoprolol 50 mg (offsets the ↑heart rate).
Level A Human clinical trials. There are randomized controlled trials (RCTs), or the compound has been approved by a regulatory agency. The most reliable level. Phase II in the Lancet. Phase III in Mexico.
Honest caveat: NOT a peptide. Not approved. ↑Heart rate, insomnia, dry mouth. A controlled substance in a number of jurisdictions. Incompatible with SSRIs/MAOIs — risk of serotonin syndrome.
Research peptides are laboratory reagents (Research Use Only). They are not medicines and are not intended for use in humans or animals.